SCHEMBL2851476

SCHEMBL2851476

OCCOCCCCC1([SiH3])CCCCO1

nearest known ligand 0.34

Predicted protein targets (top 7)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 2/20 0.34
KMT2A Q03164 2/20 0.34
THRB P10828 1/20 0.34
HTT P42858 1/20 0.34
MAPT P10636 1/20 0.34
TSHR P16473 2/20 0.33
MAPK1 P28482 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6828574 0.98 MEN1 (0.37) MEN1KMT2ATHRBHTTMAPT
SCHEMBL2853859 0.97 MEN1 (0.34) MEN1KMT2ATHRBHTTMAPT
SCHEMBL1742936 0.84 CYP4F2 (0.35) MAPT
SCHEMBL9308300 0.84 TSHR (0.33) MEN1KMT2ATHRBHTTMAPT
SCHEMBL1345314 0.83 MAPT (0.32) MAPT
SCHEMBL9309423 0.77 TSHR (0.53) TSHRMAPK1
SCHEMBL29197976 0.77 MAPT (0.33) MAPT
SCHEMBL28565055 0.76 ALDH1A1 (0.39) TSHR
SCHEMBL10352080 0.76 TSHR (0.51) TSHRMAPK1
SCHEMBL2239338 0.75

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20190071543-A1 GELS AORTECH BIOMATERIALS PTY LTD (AU) 2019-03-07 US disclosed
US-9765191-B2 Gels AORTECH INTERNATIONAL PLC (GB) 2017-09-19 US disclosed
US-20170121464-A1 GELS AORTECH BIOMATERIALS PTY LTD. (AU) 2017-05-04 US disclosed
US-20170114187-A9 GELS AORTECH INTERNATIONAL PLC (GB) 2017-04-27 US disclosed
US-20140323676-A1 GELS AORTECH INTERNATIONAL PLC (GB) 2014-10-30 US disclosed
EP-1799739-B1 GELS AORTECH INTERNAT PLC (GB) 2014-02-12 EP disclosed
US-8623986-B2 Gels Aertech International plc (GB) 2014-01-07 US disclosed
EP-2007826-B1 GELS AORTECH INT PLC (GB) 2013-12-11 EP disclosed
US-8207245-B2 Gels AORTECH INTERNATIONAL PLC (GB) 2012-06-26 US disclosed
US-20100029802-A1 Gels AORTECH INTERNATIONAL PLC (GB) 2010-02-04 US disclosed
EP-2007826-A4 GELS AORTECH BIOMATERIALS PTY LTD (AU) 2009-07-01 EP disclosed
EP-2007826-A1 GELS AorTech Biomaterials Pty Ltd (AU) 2008-12-31 EP disclosed
US-20080293844-A1 Gels AORTECH BIOMATERIALS PTY LTD (AU) 2008-11-27 US disclosed
WO-2007121513-A1 GELS AORTECH BIOMATERIALS PTY LTD (AU) 2007-11-01 WO disclosed
EP-1799739-A1 GELS AorTech Biomaterials Pty Ltd (AU) 2007-06-27 EP disclosed
WO-2006034547-A1 GELS AORTECH BIOMATERIALS PTY LTD (AU) 2006-04-06 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190071543-A1 GELS CAD, BRCA1, PUF60 MEN1 641/4885KMT2A 2191/4885THRB 2335/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.